Viatris Inc
NASDAQ:VTRS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.0772
12.1203
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
VTRS
stock under the Base Case scenario is
31.61
USD.
Compared to the current market price of 11.61 USD,
Viatris Inc
is
Undervalued by 63%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Viatris Inc.
| US |
|
Eli Lilly and Co
NYSE:LLY
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Viatris continues to face margin compression on key legacy brands like Lipitor and EpiPen, as the company’s off-patent products encounter aggressive generic competition and price erosion worldwide.
The integration of Mylan and Upjohn has proved more complex than anticipated, creating ongoing restructuring costs and uncertainty that may delay anticipated synergy savings and limit near-term earnings growth.
High debt levels stemming from the merger could constrain the company’s ability to invest in new product pipelines, leaving Viatris trailing peers with more robust research and development spending.
Viatris’s extensive global manufacturing and distribution footprint, inherited from both Mylan and Upjohn, creates economies of scale that could enhance the company’s competitiveness in emerging markets, boosting profitability in the long run.
The company’s diverse portfolio of off-patent brands and biosimilars, coupled with its pipeline expansion efforts, positions Viatris to capture market share as more biologics lose patent protection, offering new revenue streams.
Cost-savings initiatives from the merger, including divestitures of non-core assets, are on track to streamline operations further, potentially resulting in meaningful free cash flow growth and shareholder returns.
Revenue & Expenses Breakdown
Viatris Inc
Balance Sheet Decomposition
Viatris Inc
| Current Assets | 10B |
| Cash & Short-Term Investments | 1.1B |
| Receivables | 3.6B |
| Other Current Assets | 5.3B |
| Non-Current Assets | 28B |
| PP&E | 2.9B |
| Intangibles | 22.5B |
| Other Non-Current Assets | 2.6B |
| Current Liabilities | 7.4B |
| Accounts Payable | 1.3B |
| Accrued Liabilities | 2.6B |
| Other Current Liabilities | 3.4B |
| Non-Current Liabilities | 15.3B |
| Long-Term Debt | 12.5B |
| Other Non-Current Liabilities | 2.9B |
Free Cash Flow Analysis
Viatris Inc
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Viatris Inc
|
Revenue
|
14.1B
USD
|
|
Cost of Revenue
|
-8.6B
USD
|
|
Gross Profit
|
5.6B
USD
|
|
Operating Expenses
|
-4.2B
USD
|
|
Operating Income
|
1.3B
USD
|
|
Other Expenses
|
-5B
USD
|
|
Net Income
|
-3.7B
USD
|
VTRS Profitability Score
Profitability Due Diligence
Viatris Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
Viatris Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
VTRS Solvency Score
Solvency Due Diligence
Viatris Inc's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Score
Viatris Inc's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VTRS Price Targets Summary
Viatris Inc
According to Wall Street analysts, the average 1-year price target for
VTRS
is 12.38 USD
with a low forecast of 9.09 USD and a high forecast of 15.75 USD.
Dividends
Current shareholder yield for
VTRS is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
VTRS
stock under the Base Case scenario is
31.61
USD.
Compared to the current market price of 11.61 USD,
Viatris Inc
is
Undervalued by 63%.